FibroBiologics Reports $15.4 Million Net Loss and Prepares for Clinical Trials

FibroBiologics, Inc. reported a net loss of $15.4 million for the nine months ended September 30, 2025, compared to a loss of $8.1 million for the same period in 2024. The company's total operating expenses increased to $14.1 million from $10.0 million year-over-year, driven primarily by a significant rise in research and development costs, which surged to $6.6 million from $3.1 million. The increase in R&D expenses was attributed to higher costs associated with contract research organizations (CROs) and additional personnel to support clinical trial preparations. The company did not generate any revenue during this period, maintaining an accumulated deficit of $50.9 million as of September 30, 2025.

In terms of financial position, FibroBiologics reported cash and cash equivalents of $4.9 million, a decrease from $14.0 million at the end of 2024. The company’s total assets fell to $8.7 million from $16.4 million, while total liabilities decreased to $8.6 million from $13.7 million. The reduction in liabilities was primarily due to a decrease in short-term convertible debt, which was reduced from $9.2 million to $4.6 million. The company’s stockholders’ equity also declined significantly, from $2.7 million at the end of 2024 to $0.1 million by September 30, 2025.

Strategically, FibroBiologics has made notable advancements in its clinical development pipeline. The company is preparing to initiate a twelve-week Phase 1/2 clinical trial for its lead product candidate, CYWC628, aimed at treating diabetic foot ulcers in Australia, with expectations to start in early 2026. Additionally, the company formed a wholly-owned subsidiary, FibroBiologics Australia Pty Ltd, to facilitate this trial. The company is also advancing its other product candidates, including CYMS101 for multiple sclerosis and CybroCell™ for degenerative disc disease, with plans to file an Investigational New Drug (IND) application for CYMS101 in the fourth quarter of 2025.

Operationally, FibroBiologics has focused on enhancing its manufacturing capabilities, having completed the production of its master cell bank and working cell bank for CYWC628. However, the company has faced challenges in manufacturing processes, which have led to delays in clinical trial timelines. As of September 30, 2025, the company employed a limited number of personnel, reflecting its status as a smaller reporting company and emerging growth company. The company continues to explore additional funding options to support its operations and mitigate the substantial doubt regarding its ability to continue as a going concern.

Looking ahead, FibroBiologics anticipates continued operating losses as it invests in the development of its product candidates. The company plans to raise additional capital through equity offerings, debt financing, and potential collaborations. The successful development and commercialization of its product candidates remain critical to achieving profitability, which the company has yet to realize. The management has indicated that the ability to secure necessary funding will be pivotal in determining the future trajectory of the company’s operations and clinical programs.